One of the more common myths about hormone therapy (ADT) to treat prostate cancer is that its effectiveness will last only for one and a half to two years. For some men this might be true, but it is not a reality in today’s prostate cancer landscape. What makes this myth worse is that it [...]
A subgroup analysis of the phase III trials of Provenge (Sipuleucel-T) suggests that there might be a dramatic role for Provenge in African-American men who have advanced prostate cancer that has become castration-resistant (mCRPC). The analysis, which was released at the American Urological Association 2012 Annual Scientific Meeting, was headed up by Colonel David G. [...]
Cancer related fatigue (CRF) is a common problem suffered by many cancer survivors, including men with advanced prostate cancer. Whether the fatigue is a result of the cancer or of the treatment doesn’t really matter. What matters is that you are fatigued and unable to live your life as you wish. CRF can affect us [...]
Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]
The National Health Service cost regulators for England and Wales have recommended the use of Zytiga in the treatment of men with castrate resistant advanced prostate cancer. The National Institute for Health and Clinical Excellence (NICE) has published a final guidance endorsing Zytiga as an NHS treatment option for men with advanced, metastatic, castration resistant [...]